Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation

被引：0
|
作者：
Klem, P. [1 ]
Al-Omar, L. [2 ]
Cooper, J. [2 ]
Davis, S. [2 ]
Gralla, J. [2 ]
Choe, D. [1 ]
Wiseman, A. [2 ]
机构：
[1] Univ Colorado, Pharm, Aurora, CO USA
[2] Univ Colorado, Nephrol, Aurora, CO USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2017年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A174
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [41] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    [J]. PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [42] CMV Valganciclovir Prophylaxis Versus Preemptive Therapy after Renal Transplantation: Two Year Results of a Randomized Clinical Trial.
    Witzke, O.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 210 - 210
  • [43] Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients
    El Hajj, S.
    Kim, M.
    Azzi, J.
    Gabardi, S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 504 - 504
  • [44] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Brueckner, A.
    Rumore, A.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S480 - S480
  • [45] Prophylaxis against cytomegalovirus(CMV) using ganciclovir(G) or valganciclovir(V) in kidney(K) and kidney-pancreas(SPK) transplantation under antibody preconditioning
    Basu, A
    Keven, K
    Sharma, S
    Tan, H
    Khan, A
    Marcos, A
    Fung, J
    Starzl, T
    Shapiro, R
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 488 - 488
  • [46] Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
    Helantera, I.
    Kyllonen, L.
    Lautenschlager, I.
    Salmela, K.
    Koskinen, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (09) : 2026 - 2032
  • [47] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [48] Valganciclovir for the early prophylaxis of cytomegalovirus (CMV) infection after allogeneic stem cell transplantation.
    Bachier, C
    Shaughnessy, P
    Wall, D
    Grimley, M
    Carrum, G
    Freytes, C
    Callander, N
    Walsh, T
    LeMaistre, CF
    [J]. BLOOD, 2004, 104 (11) : 352B - 352B
  • [49] Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation
    Lopau, Kai
    Greser, Alexandra
    Wanner, Christoph
    [J]. CLINICAL TRANSPLANTATION, 2007, 21 (01) : 80 - 85
  • [50] CMV VIREMIA IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING BASILIXIMAB OR LOW DOSE ANTI THYMOCYTE GLOBULIN INDUCTION WITHOUT VALGANCICLOVIR PROPHYLAXIS- SINGLE CENTRE EXPERIENCE IN INDIA
    Sharma, Reetesh
    Maksana, Mayur
    Trehan, Naresh
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 2091 - 2091
12345